places clinical hold on Regenxbio’s gene therapy
Regenxbio said on Monday the U.S. FDA has placed its experimental gene therapy for a rare inherited disorder on clinical hold after spinal scans found abnormalities in five study participants, sending its shares down more than 24% in premarket trading. The therapy, RGX-121, was being developed as a one-time treatment for Hunter Syndrome, also known as MPS II, which can…

